#Pluvicto

Precision in the Crosshairs: India’s First Approved Radioligand Therapy for Advanced Prostate Cancer

Novartis launches Pluvicto in India, the first approved radioligand therapy for advanced prostate cancer. Learn how this precision treatment targets cancer cells.